Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Imatinib Stories

2012-04-05 21:10:02

Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks. The advance in mice suggests that a combination approach to therapy might stamp out chronic myeloid leukemia (CML) for good. That's in contrast to the vast majority of CML patients taking drugs like imatinib (aka Gleevec) today, who often go into remission only to see their cancer return again. It is those lingering leukemia stem cells, which stubbornly...

2012-03-28 09:58:24

Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years instead of 1 had improved recurrence-free survival and overall survival, according to a study in the March 28 issue of JAMA. "Gastrointestinal stromal tumors (GIST) are usually found in the stomach or the small intestine but can occur at any site along the gastrointestinal tract and rarely elsewhere...

2012-03-19 16:58:18

Study outlines new method to test a tumor's resistance to an experimental therapy and pinpoint the genetic culprit before testing the drug in patients–providing a new path toward personalized medicine Drug resistance is a serious problem for cancer patients–over time, a therapy that was once providing some benefit simply stops working. Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) recently discovered how cancer cells develop resistance to a drug...

2012-03-16 08:50:41

WASHINGTON, March 16, 2012 /PRNewswire/ -- Oral cancer drugs that target key enzymes in tumor cells have made significant contributions to oncology care, freeing many patients from spending long hours at infusion centers to receive their chemotherapy treatments. But new research shows that many patients using these oral medications are also on other drugs that may prevent patients from getting the full benefit from their cancer treatment, or increase the risk of side effects. (Logo:...

2012-03-12 19:51:22

21,626-person study shows 90.4 percent survival A 21,626-person study published today in the Journal of Clinical Oncology found that the five-year survival rate for children and adolescents with acute lymphoblastic leukemia (ALL), the most common childhood cancer, improved from 83.7 percent in those diagnosed during the years 1990-1994, to 90.4 percent for those diagnosed in the years 2000-2005. "The improved survival is due to using existing drugs better, not because of the...

2012-02-27 07:26:30

A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that imatinib is the treatment of choice for these patients. Imatinib, a drug that blocks the protein made by a particular cancer-causing gene, has revolutionized the treatment and...

2012-02-21 12:29:08

MD Anderson research shows promise for patients suffering from chronic pain By reformulating the common cancer drug imatinib (Gleevec®), researchers have eliminated morphine tolerance in rats — an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center. Narcotics such as morphine are a mainstay of chronic pain treatment. Over time, tolerance to the pain-relieving...

2012-02-13 12:00:00

Big Mountain Drugs, a licensed Canadian online pharmacy, is responding to the recent medication shortage by offering $25.00 off any cancer therapy order over $100.00. With coupon code feb25, patients, their caregivers, and hospitals can save when they buy cancer medications such as generic Gleevec or Tarceva. Vancouver, BC (PRWEB) February 13, 2012 Big Mountain Drugs, a leading Canadian online pharmacy, has partnered with BreastCancerCare.us to release a new coupon specifically for cancer...

2012-02-01 00:26:00

EAST HANOVER, N.J., Feb. 1, 2012 /PRNewswire/ -- Novartis announced today that following a priority review, the US Food and Drug Administration (FDA) has approved an update to the Gleevec(®) (imatinib mesylate)[*] tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial. This treatment regimen...

2012-01-31 17:14:00

Confirmatory trials show significantly prolonged survival in patients; drug granted regular approval SILVER SPRING, Md., Jan. 31, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today's action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the...